/ Print /

IN THE PIPELINE

Top 5 specialty drug management issuesThe 13th edition EMD Serono Specialty Digest outlines top specialty drug management issues health plans face.
How pharma reps impact physician prescribingA new study led by The University of California researchers and published in JAMA reveals surprising findings.
Amputation risk possible with diabetes drugs, FDA warnsBased on new data from 2 large clinical trials, FDA is warning that these blockbuster type 2 diabetes medications can cause an increased risk of leg and foot amputations.
FDA expands cystic fibrosis treatmentFDA expanded the use of ivacaftor (Kalydeco, Vertex Pharmaceuticals) to treat cystic fibrosis.
Immuno-oncology bladder drug wins approvalSoon after approving the same drug for metastatic Merkel cell carcinoma, FDA approved immuno-oncology avelumab (Bavencio) for locally advanced or metastatic urothelial carcinoma.
New FDA lead ushers in new eraScott Gottlieb, MD, was sworn in as the new FDA commissioner and ushers in a new era.
Costly new ALS treatment approvedFDA recently approved the first new treatment for amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, in more than 20 years.
Campaign gears up to combat high drug pricesWalmart, CVS Health, and a number of other healthcare organizations are supporting a new multi-million dollar consumer campaign to combat high prescription drug prices.
FDA approves first targeted leukemia drug for certain patients, plus 2 moreLate last week, FDA approved a new drug to treat acute myeloid leukemia (AML), the first treatment for Batten disease, and expanded the use of a current drug to treat liver cancer.
New abuse-deterrent opioid availableA new abuse-deterrent painkiller - oxycodone hydrochloride (RoxyBond, Inspirion Delivery Services) - will be available soon after receiving FDA approval.